SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+18.51%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$447M
AUM Growth
+$447M
(+0.78%)
Cap. Flow
+$10.3M
Cap. Flow
% of AUM
2.3%
Top 10 Holdings %
Top 10 Hldgs %
48.85%
Holding
81
New
11
Increased
34
Reduced
11
Closed
21
Top Buys
| 1 |
Pliant Therapeutics
PLRX
|
$17.3M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$11.3M |
| 3 |
Scholar Rock
SRRK
|
$7.92M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$7.76M |
| 5 |
Ascendis Pharma
ASND
|
$6.4M |
Top Sells
| 1 |
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
|
$25.7M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$9.84M |
| 3 |
Protagonist Therapeutics
PTGX
|
$6.6M |
| 4 |
Sarepta Therapeutics
SRPT
|
$6.4M |
| 5 |
ADC Therapeutics
ADCT
|
$5.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $31.3M | 6.85% |
400,014
+28,573
| +8% | +$2.24M |
|
2
Merus
MRUS
$4.98B
| $28.6M | 6.26% |
680,845
+45,406
| +7% | +$1.91M |
|
3
Insmed
INSM
$28.8B
| $25.7M | 5.62% |
372,230
+24,535
| +7% | +$1.69M |
|
|
VRNA
4
Verona Pharma
VRNA
$9.16B
| $24M | 5.24% |
516,014
+167,148
| +48% | +$7.76M |
|
5
Akero Therapeutics
AKRO
$3.74B
| $20.6M | 4.5% |
739,563
+99,723
| +16% | +$2.77M |
|
6
Veracyte
VCYT
$2.39B
| $19.9M | 4.36% |
503,281
+32,716
| +7% | +$1.3M |
|
7
Erasca
ERAS
$445M
| $18.9M | 4.14% |
7,543,901
+597,413
| +9% | +$1.5M |
|
|
8
Pliant Therapeutics
PLRX
$101M
| $17.3M | 3.79% |
+1,315,601
| New | +$17.3M |
|
|
9
Syndax Pharmaceuticals
SNDX
$1.41B
| $16.3M | 3.56% |
1,230,400
+851,654
| +225% | +$11.3M |
|
10
Avidity Biosciences
RNA
$5.99B
| $15.8M | 3.46% |
543,651
+68,096
| +14% | +$1.98M |
|
11
Rhythm Pharmaceuticals
RYTM
$6.85B
| $15.3M | 3.35% |
273,896
+18,318
| +7% | +$1.03M |
|
|
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15M | 3.27% |
179,085
+11,975
| +7% | +$1M |
|
13
UroGen Pharma
URGN
$900M
| $11.9M | 2.61% |
1,120,473
+219,344
| +24% | +$2.34M |
|
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$2.25B
| $10M | 2.19% |
598,952
-145,640
| -20% | -$2.44M |
|
15
Kodiak Sciences
KOD
$478M
| $9.95M | 2.18% |
1,000,000
+500,000
| +100% | +$4.98M |
|
|
PSTX
16
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $9.72M | 2.13% |
1,012,307
-2,675,241
| -73% | -$25.7M |
|
17
Oric Pharmaceuticals
ORIC
$994M
| $9.51M | 2.08% |
1,178,300
+78,810
| +7% | +$636K |
|
18
TELA Bio
TELA
$70.5M
| $9.26M | 2.03% |
3,065,649
+1,940,721
| +173% | +$5.86M |
|
|
19
Scholar Rock
SRRK
$3.14B
| $7.92M | 1.73% |
+183,243
| New | +$7.92M |
|
20
Wave Life Sciences
WVE
$1.53B
| $7.53M | 1.65% |
608,897
-18,655
| -3% | -$231K |
|
21
Cogent Biosciences
COGT
$1.69B
| $7.18M | 1.57% |
921,137
-300,225
| -25% | -$2.34M |
|
|
22
Ascendis Pharma
ASND
$11.8B
| $7.09M | 1.55% |
51,491
+46,491
| +930% | +$6.4M |
|
23
Disc Medicine
IRON
$2.07B
| $7M | 1.53% |
110,381
+6,519
| +6% | +$413K |
|
24
Celldex Therapeutics
CLDX
$1.47B
| $6.69M | 1.46% |
264,560
+119,560
| +82% | +$3.02M |
|
25
Elutia
ELUT
$96.7M
| $6.67M | 1.46% |
1,782,271
+136,463
| +8% | +$510K |
|